Incretin

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Retrieved on: 
星期四, 五月 2, 2024
FDA, Patient, Effectiveness, Incretin, Woman, Food, Health, Bremelanotide, Trial of the century, Human, Weight loss, Research, Peptide, Melanocortin, IND, KOL, University college, Therapy, Treatment, Rat, Standard of care, PTN, Quality of life, Calendar, Pharmaceutical industry

The study is designed to enroll up to 60 patients actively on tirzepatide at approximately five trial sites in the U.S.

Key Points: 
  • The study is designed to enroll up to 60 patients actively on tirzepatide at approximately five trial sites in the U.S.
  • The primary endpoint of the trial is to demonstrate the safety and increased efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight.
  • Patients will be treated with tirzepatide-only for four weeks, have eligibility confirmed, then randomized to one of four treatment regimens.
  • "Therapeutic options for obesity treatment requires multiple pathways to safely, effectively, and consistently treat and maintain weight loss.

Valbiotis publishes its annual accounts 2023

Retrieved on: 
星期五, 五月 3, 2024
FDA, Sales management, Partnership, Hypercholesterolemia, Sleep, INSIGHT, Prevalence, Insulin resistance, Inflammation, DSM-IV codes, Food, Communication, Cholecalciferol, Executive Committee, Pharmacist, Pharmacy, Volunteering, INAF, Phase, Practitioner, Incretin, EFSA, Safety, Omega-3 fatty acid, Agonal respiration, Human, LDL, Marketing, Prediabetes, NAFLD, Endocrine gland, NDI, Food and Drug Administration, Meal, Commercial, Dietary supplement, Blood pressure, Patient, Statutory auditor, Metabolism, Hypertension, Cardiovascular disease, Bank statement, Pharmaceutical industry

Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.

Key Points: 
  • Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.
  • By accelerating its structuring, Valbiotis also laid the foundations for 2024, which promises to be particularly fruitful.
  • The Company's 2023 financial statements, drawn up in accordance with IFRS, were approved by the Board of Directors on April 23, 2024.
  • They have been audited by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com/en (investors section).

The Incretin Impact: A New Era in Metabolic Disease and Obesity Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
星期二, 四月 16, 2024
University, Incretin, DSM-IV codes, All India Mahila Congress, Diabetes, PET, Entrepreneurship, Drug discovery, Obesity, University of Copenhagen, Senior, Magnetic resonance imaging, MRI, Drug development, Chemistry, Gelastic seizure

TORONTO , April 16, 2024 /PRNewswire-PRWeb/ -- With the demonstrated efficacy and approvals of recent incretin-based therapies for the treatment of diabetes and obesity, one might think this is it for incretins. But really, it is just the beginning — given the possibilities for new combinations, different formulations and more indications throughout metabolic diseases and beyond.

Key Points: 
  • Attendees will learn why the future of incretin drug development will likely expand with different combinations, formulations and disease indications.
  • It is currently a very exciting time within drug development for incretins, but there is still a lot we do not know.
  • How can we better understand their effects and advance drug development in obesity and metabolic disease?
  • Register for this webinar today to learn about incretins, the current status of incretin drug development and the speakers' perspectives on the future of incretin drug development.

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Retrieved on: 
星期二, 四月 9, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Internal medicine, Incretin, Obesity, AstraZeneca, Novo Nordisk, Cardiology, University college, Patient, DSM-IV codes, Weight loss, NAMS, Doctor of Philosophy, MD, Biology, PPD, Inc., Book, Ageing, Pharmaceutical industry

BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors.

Key Points: 
  • BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors.
  • "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs.
  • "I'm excited to join the board of BioAge at this pivotal juncture, as the company progresses azelaprag into Phase 2 trials in obesity," said Davidson.
  • I look forward to working with the team to bring this promising therapy to patients in need."

Svetlana Mojsov named 2024 recipient of the Pearl Meister Greengard Prize

Retrieved on: 
星期三, 二月 28, 2024
Glucagon, Diabetes, Rockefeller's, Woman, Pearl Meister Greengard Prize, Rockefeller University, Dicarboxylic acid, Obesity, Incretin, Vincent Astor, Zookeeper, Insulin, Pancreas, Massachusetts General Hospital, Research, Nobel Prize, Partnership, Pharmaceutical industry

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Svetlana Mojsov , whose research into hormonal triggers for insulin production led to groundbreaking treatments for diabetes and obesity, will receive the 2024 Pearl Meister Greengard Prize, The Rockefeller University announced today.

Key Points: 
  • NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Svetlana Mojsov , whose research into hormonal triggers for insulin production led to groundbreaking treatments for diabetes and obesity, will receive the 2024 Pearl Meister Greengard Prize, The Rockefeller University announced today.
  • Mojsov, a research associate professor at Rockefeller, will be honored at a ceremony on campus on April 17.
  • The Pearl Meister Greengard Prize was established by the late Paul Greengard , the Vincent Astor Professor at Rockefeller, and his wife, the sculptor Ursula von Rydingsvard.
  • Visit this page to register for the Pearl Meister Greengard Prize ceremony and learn more about the award.

BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics

Retrieved on: 
星期二, 二月 13, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Therapy, OrbiMed, Body composition, Obesity, Incretin, Ageing, Weight loss, Venture round, Doctor of Philosophy, DSM-IV codes, Pivotal, Biology, Muscle atrophy, Investment, Pharmaceutical industry

BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.

Key Points: 
  • BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.
  • In connection with the financing, James Healy, M.D., Ph.D., managing partner at Sofinnova Investments, will join BioAge as Chairman of the Board, and Patrick Enright, managing director at Longitude Capital, will join as Board Director.
  • In preclinical studies, azelaprag doubled the weight loss achieved on incretin drugs with improvements in body composition and muscle function.
  • “We’re thrilled to partner with a top-tier syndicate of investors and pharma companies at the forefront of developing novel therapeutics for metabolic diseases,” said Kristen Fortney, Ph.D., CEO and co-founder of BioAge.

Carmot Therapeutics Announces Completion of Acquisition by Roche

Retrieved on: 
星期一, 一月 29, 2024
Diabetes, Obesity, DSM-IV codes, Patient, Weight loss, Acquisition, Therapy, Incretin, Overweight, Metabolism, Pharmaceutical industry

BERKELEY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, today announced that its acquisition by the Roche Group (Roche) has been completed.

Key Points: 
  • BERKELEY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, today announced that its acquisition by the Roche Group (Roche) has been completed.
  • Having successfully completed its acquisition of Carmot, Roche obtains access to Carmot’s current R&D portfolio including all clinical and pre-clinical assets, as well as exclusive access to Carmot’s innovative Chemotype Evolution discovery platform in metabolism, further strengthening Roche’s R&D efforts and portfolio across cardiovascular and metabolic diseases.
  • Carmot and its employees will join the Roche Group as part of Roche’s Pharmaceuticals Division.
  • Roche has acquired all outstanding shares and options of Carmot at a purchase price of $2.7 billion.

Perpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug Discovery

Retrieved on: 
星期五, 十二月 1, 2023
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Intarsia, Initial public offering, Amylin Pharmaceuticals, GSK plc, Vancomycin, Senior, Head, Protein, APS, Artificial intelligence, Machine learning, Medication, Eli Lilly, Therapy, Perpetual, Eli Lilly and Company, MD, Harvard Medical School, Deep learning, Drug discovery, Drug development, Spotlight Innovation, Doctor of Philosophy, Incretin, Autoimmunity, Fine chemical, Management, Chemistry

Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery.

Key Points: 
  • Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery.
  • “Perpetual Medicines is capitalizing on recent advances in computational modeling based on artificial intelligence, deep learning and machine learning that enable access for the first time to the enormous, untapped peptide chemical space for drug discovery,” said Dr. Blanchard.
  • This approach has the potential to accelerate peptide drug discovery, reduce cost, and increase the quality of drug candidates.
  • Ved Srivastava, PhD, Chief Technology Officer – Dr. Srivastava brings to Perpetual Medicines more than 25 years of experience in the discovery and development of peptide therapeutics.

BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization

Retrieved on: 
星期四, 十月 26, 2023
Health, Fitness & Nutrition, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Science, Lilly, Eli Lilly and Company, Ageing, Concept, Biomarker, Therapy, Heart, Obesity, Weight loss, Apelin, Doctor of Philosophy, Agonal respiration, Maintenance, Exercise, Metabolism, Drug development, Incretin, Muscle atrophy, Biology, Amgen, Bed rest, Chemistry, Central nervous system, Pharmaceutical industry, Dietary supplement, Chorus

As part of the collaboration, Lilly will also provide BioAge with tirzepatide.

Key Points: 
  • As part of the collaboration, Lilly will also provide BioAge with tirzepatide.
  • “We are thrilled to work directly with the clinical development experts at Chorus and benefit from Lilly’s expertise in obesity drug development,” said Kristen Fortney, PhD, CEO and co-founder of BioAge.
  • “Our Phase 2 trial is designed to assess whether azelaprag can substantially increase the weight loss achieved with drugs of the incretin class.
  • Apelin signaling has demonstrated multiple benefits in energy metabolism in mouse models, including increased insulin sensitivity and reduction in fat mass.

Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity

Retrieved on: 
星期四, 一月 12, 2023
Bimagrumab, Type 2 diabetes, Incretin, Safety, Weight loss, Overweight, Therapy, Patient, Muscle, Obesity, Weight, Pharmaceutical industry

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage biopharmaceutical company advancing novel therapeutics for cardiometabolic diseases, today announced that the BELIEVE Phase 2b study to assess the safety and efficacy of bimagrumab alone and in combination with semaglutide for the treatment of obesity has begun enrolling at sites in the U.S., Australia, and New Zealand.

Key Points: 
  • It is the only candidate in clinical development for the treatment of obesity that drives substantial fat loss while also increasing muscle mass.
  • "We are thrilled with the enthusiasm for the study and have already enrolled close to 20% of our targeted patients."
  • BELIEVE is a randomized, placebo-controlled, 48-week global Phase 2b study targeting enrollment of 450 non-diabetic patients with overweight or obesity who will receive placebo or bimagrumab, with or without semaglutide.
  • The study will assess the safety and efficacy of bimagrumab both as a monotherapy and when co-administered with semaglutide.